BMY
Bristol-Myers Squibb Co.
$61.48
-2.41%
2026-10-23
About Bristol-Myers Squibb Co.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Key Fundamentals
P/E Ratio
13.85
Forward P/E
9.58
EPS (TTM)
$4.54
ROE
46.6%
Revenue Growth (YoY)
5.7%
Profit Margin
18.9%
Debt/Equity
201.86
Dividend Yield
4.0%
Price/Book
5.75
Beta
0.23
Market Cap
$128.41B
Avg Volume (10D)
13.5M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$68.64
60D Low
$56.15
Avg Volume
11.7M
Latest Close
$61.48
Get breakout alerts for BMY
Sign up for Breakout Scanner to receive daily notifications when BMY triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Bristol-Myers Squibb Co. (BMY) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors BMY daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. BMY operates in the Healthcare sector within the Drug Manufacturers - General industry. Data is provided for informational purposes only and does not constitute financial advice.